FIS reengineers private capital suite as cloud-native SaaS solution

Investing.comTuesday, September 23, 2025 at 12:45:13 PM
FIS reengineers private capital suite as cloud-native SaaS solution
FIS has unveiled a reengineered private capital suite, now offered as a cloud-native SaaS solution. This transformation is significant as it enhances operational efficiency and accessibility for clients in the financial sector, allowing them to leverage advanced technology for better investment management. The move reflects FIS's commitment to innovation and meeting the evolving needs of its customers.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
FIS’s SWOT analysis: strategic moves reshape payment giant’s stock outlook
PositiveFinancial Markets
FIS has recently conducted a SWOT analysis that highlights strategic moves aimed at reshaping its stock outlook. This analysis is significant as it provides insights into how the company plans to navigate the competitive payment landscape, potentially boosting investor confidence and stock performance. Understanding these strategies can help stakeholders gauge the future direction of FIS and its impact on the broader financial market.
Latest from Financial Markets
Russians ramp up spending on foreign holidays – data
PositiveFinancial Markets
Recent data shows that Russians are significantly increasing their spending on foreign holidays, with Türkiye emerging as the top travel destination. This trend highlights a growing interest in international travel among Russians, which could have positive implications for the tourism industry and local economies in popular destinations.
F.D.A.’s Approval of Drug for Autism Upends Review Process
PositiveFinancial Markets
The FDA's recent approval of a new drug for autism marks a significant shift in the review process for treatments targeting this condition. This decision not only opens doors for innovative therapies but also highlights the growing recognition of autism in the healthcare landscape. It matters because it could lead to improved quality of life for individuals with autism and their families, offering hope where there was previously limited options.
Drone Swarm Software Maker Auterion Raises $130 Million
PositiveFinancial Markets
Auterion, a defense tech startup, has successfully raised $130 million in a Series B funding round, signaling strong investor confidence in its innovative drone software. This funding will enable Auterion to expand its technology for drone warfare, which is increasingly relevant in modern defense strategies. CEO Lorenz Meier discussed the implications of this funding on Bloomberg Tech, highlighting the potential for enhanced capabilities in military operations. This development is significant as it reflects the growing importance of advanced technology in defense and security.
FAT Brands engages advisers amid restructuring talks with bondholders - WSJ
NeutralFinancial Markets
FAT Brands is currently in discussions with advisers as it navigates restructuring talks with its bondholders. This development is significant as it highlights the company's efforts to manage its financial obligations and stabilize its operations. The outcome of these talks could impact the future of the brand and its ability to continue expanding in the competitive food industry.
Trump Blasts UN Over Immigration, Climate
NegativeFinancial Markets
In a fiery address at the United Nations General Assembly, President Donald Trump criticized the UN for not supporting his diplomatic initiatives, dismissing climate change as a hoax and labeling uncontrolled migration as the foremost political issue today. This speech highlights Trump's ongoing tension with international bodies and his controversial stance on global issues, which could impact future diplomatic relations and global cooperation.
Trump links autism to Tylenol and vaccines, claims not backed by science
NegativeFinancial Markets
Former President Donald Trump has stirred controversy by linking autism to the use of Tylenol and vaccines, a claim that lacks scientific backing. This assertion raises concerns as it may contribute to misinformation about autism and vaccine safety, potentially influencing public perception and health decisions. It's crucial to rely on credible scientific research when discussing such sensitive topics.